Ligand Pharmaceuticals Inc (LGND)
113.30
-0.50
(-0.44%)
USD |
NASDAQ |
Dec 24, 12:00
Ligand Pharmaceuticals Cash from Investing (Quarterly): -46.51M for Sept. 30, 2024
Cash from Investing (Quarterly) Chart
Sep '18
Jan '19
May '19
285.00
270.00
255.00
240.00
Historical Data
Cash From Investing Definition
Cash from Investing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall investing activities of the company. A few examples of investing activities include net change in PP&E, and net divestitures.
Cash from Investing (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
Cash from Investing (Quarterly) Benchmarks
| Cellectar Biosciences Inc | 0.00 |
| Revance Therapeutics Inc | 23.29M |
| Pieris Pharmaceuticals Inc | 0.142M |
| Zymeworks Inc | 72.26M |
| CNS Pharmaceuticals Inc | 0.00 |
Cash from Investing (Quarterly) Related Metrics
| Cash from Operations (Quarterly) | 36.53M |
| Cash from Financing (Quarterly) | 55.08M |
| Free Cash Flow | 6.968M |
| Free Cash Flow Per Share (Quarterly) | 1.210 |
| Free Cash Flow to Equity (Quarterly) | 22.29M |
| Free Cash Flow to Firm (Quarterly) | 22.29M |
| Free Cash Flow Yield | 0.34% |